Literature DB >> 36098834

The role and function of CLU in cancer biology and therapy.

Yefei Zhang1, Xiang Lv1, Liming Chen2, Yan Liu3.   

Abstract

Clusterin (CLU) is a highly evolutionary conserved glycoprotein with multiple isoform-specific functions and is widely distributed in different species. Accumulated evidence has shown the prominent role of CLU in regulating several essential physiological processes, including programmed cell death, metastasis, invasion, proliferation and cell growth via regulating diverse signaling pathways to mediate cancer progression in various cancers, such as prostate, breast, lung, liver, colon, bladder and pancreatic cancer. Several studies have revealed the potential benefit of inhibiting CLU in CLU inhibition-based targeted cancer therapies in vitro, in vivo or in human, suggesting CLU is a promising therapeutic target. This review discusses the multiple functions and mechanisms of CLU in regulating tumor progression of various cancers and summarizes the inhibitors of CLU used in CLU inhibition-based targeted cancer therapies.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer progression; Cancer therapy; Clusterin (CLU)

Year:  2022        PMID: 36098834     DOI: 10.1007/s10238-022-00885-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  134 in total

Review 1.  Programmed cell death - strategy for maintenance cellular organisms homeostasis.

Authors:  Mirosław Godlewski; Agnieszka Kobylińska
Journal:  Postepy Hig Med Dosw (Online)       Date:  2016-12-20       Impact factor: 0.270

Review 2.  Clusterin.

Authors:  Steve E Jones; Catherine Jomary
Journal:  Int J Biochem Cell Biol       Date:  2002-05       Impact factor: 5.085

Review 3.  Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy.

Authors:  Prakash Priyadarshi Praharaj; Srimanta Patra; Debasna Pritimanjari Panigrahi; Samir Kumar Patra; Sujit Kumar Bhutia
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-29       Impact factor: 10.680

4.  Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor.

Authors:  Tracy Criswell; Meghan Beman; Shinako Araki; Konstantin Leskov; Eva Cataldo; Lindsey D Mayo; David A Boothman
Journal:  J Biol Chem       Date:  2005-02-02       Impact factor: 5.157

5.  Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

Authors:  S Bettuzzi; P Davalli; S Davoli; O Chayka; F Rizzi; L Belloni; D Pellacani; G Fregni; S Astancolle; M Fassan; A Corti; R Baffa; A Sala
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

6.  In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.

Authors:  Qibiao Wu; Yahui Tian; Jian Zhang; Xinyuan Tong; Hsinyi Huang; Shuai Li; Hong Zhao; Ying Tang; Chongze Yuan; Kun Wang; Zhaoyuan Fang; Lei Gao; Xin Hu; Fuming Li; Zhen Qin; Shun Yao; Ting Chen; Haiquan Chen; Gong Zhang; Wanting Liu; Yihua Sun; Luonan Chen; Kwok-Kin Wong; Kai Ge; Liang Chen; Hongbin Ji
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

Review 7.  Programmed cell death in animal development and disease.

Authors:  Yaron Fuchs; Hermann Steller
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

Review 8.  Clusterin: a key player in cancer chemoresistance and its inhibition.

Authors:  Tomas Koltai
Journal:  Onco Targets Ther       Date:  2014-03-20       Impact factor: 4.147

Review 9.  Plant Cell Cultures as a Tool to Study Programmed Cell Death.

Authors:  Massimo Malerba; Raffaella Cerana
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

10.  Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity.

Authors:  Zhipeng Chen; Zhenzhen Fan; Xiaowei Dou; Qian Zhou; Guandi Zeng; Lu Liu; Wensheng Chen; Ruirui Lan; Wanting Liu; Guoqing Ru; Lei Yu; Qing-Yu He; Liang Chen
Journal:  Theranostics       Date:  2020-09-16       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.